Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Onalespib

Generic Name: Onalespib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₁N_₃O_₃

CAS Number: 912999-49-6

Unique Ingredient Identifier: Q7Y33N57ZZ

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions

No associated conditions information available.

Clinical Trials

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Phase 1

Completed

Posted: 2016/09/13

Sponsor:National Cancer Inst...

ID:NCT02898207

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Phase 2

Terminated

Posted: 2015/10/09

Sponsor:National Cancer Inst...

ID:NCT02572453

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1

Completed

Posted: 2015/08/28

Sponsor:National Cancer Inst...

ID:NCT02535338

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Posted: 2015/07/21

Sponsor:National Cancer Inst...

ID:NCT02503709

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1

Terminated

Posted: 2015/06/17

Sponsor:National Cancer Inst...

ID:NCT02474173

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy